In the long river of medicine, IgG4-related disease is a relatively “young” but high-profile area, and our understanding of it has undergone a profound transformation. In the past, many patients suffering from diseases such as their own immunopanic pancreas, sclerosis and post-peritoneal fibrosis faced confusion and misdiagnosis in their medical treatment. Because of these seemingly different systems and organs, these diseases have been studied and treated as separate diseases for a long time.
However, as medical research deepens, scientists gradually discover the hidden links between them, the concept of IgG4-related diseases is born and becomes clearer. The core characteristics of IgG4-related diseases are the large number of IgG4-positive plasma cells immersed, tissue fibrosis, and increased serum IgG4 levels in the affected tissue. In the past, for example, self-immunized pancreas have been understood and treated only in the context of local inflammation of pancreas, often with unsatisfactory results.
But when we realized that it was a manifestation of IgG4-related diseases, we had a major shift in our treatment strategies from the point of view of overall immunization disorders. There has been a shift from local treatment of disorders, such as painkilling for pancreas alone, inhibition of pancreas, etc., to immuno-modified treatment. This change has significantly improved the effectiveness of treatment, with many patients having better control of pancreas, significantly reduced symptoms and improved quality of life.
In the area of diagnosis, changes in perceptions have also brought about new thinking and approaches. In the past, visceral choreography, such as cholesterol imaging, was used to determine the narrowness and congestion of the cholesterol, with treatment also focusing on cholesterol decomposition and local inflammation control.
Today, sero-IgG4 tests become an important diagnostic aid. When the patient’s serum IgG4 levels are found to be significantly higher, and when they are accompanied by tissue characteristics such as a thicker cholesterol wall and a large number of IgG4 positive plasma cell immersion, it is more accurately diagnosed as IgG4-related cholesterolitis. This not only avoids unnecessary surgical detection, but also provides patients with a more accurate programme of immunosuppression treatment, which significantly increases the success rate of treatment and reduces the incidence of complications. This is also the case for post-peritoneal fibrosis, which was used as a simple post-peritoneal filamental irritation disease, mostly by surgically removed fibrosis, but with a high rate of post-operative relapse.
Now, with the inclusion of IgG4-related diseases, the treatment of immunosuppressants can inhibit the immune response at its root, deter further growth of fibre tissues, effectively reduce the risk of relapse and improve long-term patient prognosis. This change in perception is also continuing to drive new research directions.
Scientists have tried to explore in depth the mechanisms for the occurrence of IgG4-related diseases, and what have led to the abnormality of the organism’s immune system, which has led to a large increase in IgG4 positive plasma cells and leaching them into various tissues? The answers to these questions will help to develop more targeted treatment drugs and methods.
For example, a number of studies are currently exploring target-oriented treatment for IgG4 molecules or associated immunocellular signal access, which, if successful, will bring a revolutionary breakthrough in the treatment of such diseases. From an isolated view of the changes in the disease of organs to a unified classification of IgG4-related diseases, from simple treatment of symptoms to accurate immunomodified treatment, the change in our perception of IgG4-related diseases has undoubtedly given patients more hope. It allows us, in the face of such complex diseases, to develop more readily scientifically sound treatments, and it inspires medical scientists to explore in depth and look forward to overcoming the disease ‘ s challenges in the future and to restoring the health of their patients.
